Copy Link Print Information

Evolocumab

(Synonyms: AMG 145)
3 Cited Publications
Customer Review

Based on 3 publication(s) in Google Scholar

Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation.

For research use only. We do not sell to patients.

  • Purity: 98.4%
  • CAS No.: 1256937-27-5
  • Molecular Weight:141.8 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Evolocumab
  • Experimental Validation Results for Evolocumab
  • Experimental Validation Results for Evolocumab
  • Experimental Validation Results for Evolocumab
  • Experimental Validation Results for Evolocumab
  • Experimental Validation Results for Evolocumab
  • Experimental Validation Results for Evolocumab
  • Experimental Validation Results for Evolocumab
  • Evolocumab Chemical Structure
    Evolocumab Chemical Structure
CAS No.: 1256937-27-5
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Evolocumab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Evolocumab

More
Customer Validation & Images
Histological Imaging/StainingWBIn Vivo Efficacy Study
  • Histological Imaging/Staining
  • Histological Imaging/Staining
  • WB
  • Histological Imaging/Staining
  • In Vivo Efficacy Study

All NF-κB Isoforms

More

All Toll-like Receptor (TLR) Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG2 lambda

  • 1/16

    Immobilized PCSK9 Protein, Human can bind Evolocumab. The EC50 for this effect is 574 ng/mL.

  • 1/16

    Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Evolocumab (anti-PCSK9) (HY-P9930). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 lambda (HY-P991206). Black-Unlabelled control, cells without incubation with primary antibody.

  • 1/16

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996. [Abstract]

    Customer Validation
     There was no difference in the 24-hour myocardial infarct size between the Evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) treatment group and the myocardial infarction (MI) group.

  • 1/16

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996. [Abstract]

    Customer Validation
     The degree of myocardial fibrosis in the MI + evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) group was lower than that in the MI + vehicle (Veh) group.

  • 1/16

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996. [Abstract]

    Customer Validation
     Evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) decreased the collagen I, collagen III, and α-SMA proteins induced by the myocardial infarction (MI) model in rats.

  • 1/16

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996. [Abstract]

    Customer Validation
     WGA staining showed that evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) treatment could reduce cardiomyocyte volume after myocardial infarction in a rat MI model.

  • 1/16

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996. [Abstract]

    Customer Validation
     Evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) treatment improved cardiac function after myocardial infarction in myocardial infarction model rats.

  • Evolocumab Chemical Structure
    1/16
  • Evolocumab
  • Immobilized PCSK9 Protein, Human can bind Evolocumab. The EC50 for this effect is 574 ng/mL.
  • Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Evolocumab (anti-PCSK9) (HY-P9930). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 lambda (HY-P991206). Black-Unlabelled control, cells without incubation with primary antibody.